SHCM
ALXN

Sachem Head Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Sachem Head Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-635,000
Closed -$77M – 17
2017
Q1 		$77M Sell
635,000
-300,000
-32% -$38.7M 2.49% 14
2016
Q4 		$114M Buy
+935,000
New +$114M 4.38% 11

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sachem Head Capital Management's ALXN Position: Q2 2017 in Review

Sachem Head Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 635,000 shares — an estimated $77M sold.

Sachem Head Capital Management first reported a position in ALXN in Q4 2016 and held it in 2 quarters. The position peaked at $114M in Q4 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Sachem Head Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Sachem Head Capital Management sold 635,000 Alexion Pharmaceuticals shares in Q2 2017, an estimated $77M.
  • Sachem Head Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Sachem Head Capital Management's Alexion Pharmaceuticals position peaked at $114M in Q4 2016.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Sachem Head Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.